INTRODUCTION: Secretory phospholipases A2 (sPLA2) hydrolyze phospholipids in cell membranes and extracellular structures such as pulmonary surfactant. This study tests the hypothesis that sPLA2 are elevated in human lungs during acute respiratory distress syndrome (ARDS) and that sPLA2 levels are associated with surfactant injury by hydrolysis of surfactant phospholipids. METHODS: Bronchoalveolar lavage (BAL) fluid was obtained from 18 patients with early ARDS (<72 hours) and compared with samples from 10 healthy volunteers. Secreted phospholipase A2 levels were measured (enzyme activity and enzyme immunoassay) in conjunction with ARDS subjects' surfactant abnormalities including surfactant phospholipid composition, large and small aggregates distribution and surface tension function. RESULTS: BAL sPLA2 enzyme activity was markedly elevated in ARDS samples relative to healthy subjects when measured by ex vivo hydrolysis of both phosphatidylglycerol (PG) and phosphatidylcholine (PC). Enzyme immunoassay identified increased PLA2G2A protein in the ARDS BAL fluid, which was strongly correlated with the sPLA2 enzyme activity against PG. Of particular interest, the authors demonstrated an average depletion of 69% of the PG in the ARDS sample large aggregates relative to the normal controls. Furthermore, the sPLA2 enzyme activity against PG and PC ex vivo correlated with the BAL recovery of in vivo PG and PC, respectively, and also correlated with the altered distribution of the large and small surfactant aggregates. CONCLUSIONS: These results support the hypothesis that sPLA2-mediated hydrolysis of surfactant phospholipid, especially PG by PLA2G2A, contributes to surfactant injury during early ARDS.
INTRODUCTION: Secretory phospholipases A2 (sPLA2) hydrolyze phospholipids in cell membranes and extracellular structures such as pulmonary surfactant. This study tests the hypothesis that sPLA2 are elevated in human lungs during acute respiratory distress syndrome (ARDS) and that sPLA2 levels are associated with surfactant injury by hydrolysis of surfactant phospholipids. METHODS: Bronchoalveolar lavage (BAL) fluid was obtained from 18 patients with early ARDS (<72 hours) and compared with samples from 10 healthy volunteers. Secreted phospholipase A2 levels were measured (enzyme activity and enzyme immunoassay) in conjunction with ARDS subjects' surfactant abnormalities including surfactant phospholipid composition, large and small aggregates distribution and surface tension function. RESULTS: BAL sPLA2 enzyme activity was markedly elevated in ARDS samples relative to healthy subjects when measured by ex vivo hydrolysis of both phosphatidylglycerol (PG) and phosphatidylcholine (PC). Enzyme immunoassay identified increased PLA2G2A protein in the ARDS BAL fluid, which was strongly correlated with the sPLA2 enzyme activity against PG. Of particular interest, the authors demonstrated an average depletion of 69% of the PG in the ARDS sample large aggregates relative to the normal controls. Furthermore, the sPLA2 enzyme activity against PG and PC ex vivo correlated with the BAL recovery of in vivo PG and PC, respectively, and also correlated with the altered distribution of the large and small surfactant aggregates. CONCLUSIONS: These results support the hypothesis that sPLA2-mediated hydrolysis of surfactant phospholipid, especially PG by PLA2G2A, contributes to surfactant injury during early ARDS.
Authors: Norbert Degousee; Farideh Ghomashchi; Eva Stefanski; Alan Singer; Brian P Smart; Niels Borregaard; Reinhardt Reithmeier; Thomas F Lindsay; Cornelia Lichtenberger; Walter Reinisch; Gerard Lambeau; Jonathan Arm; Jay Tischfield; Michael H Gelb; Barry B Rubin Journal: J Biol Chem Date: 2001-12-06 Impact factor: 5.157
Authors: W Y Park; R B Goodman; K P Steinberg; J T Ruzinski; F Radella; D R Park; J Pugin; S J Skerrett; L D Hudson; T R Martin Journal: Am J Respir Crit Care Med Date: 2001-11-15 Impact factor: 21.405
Authors: Alan G Singer; Farideh Ghomashchi; Catherine Le Calvez; James Bollinger; Sofiane Bezzine; Morgane Rouault; Martin Sadilek; Eric Nguyen; Michel Lazdunski; Gerard Lambeau; Michael H Gelb Journal: J Biol Chem Date: 2002-09-30 Impact factor: 5.157
Authors: Mac B Robinson; Deepak A Deshpande; Jeffery Chou; Wei Cui; Shelly Smith; Carl Langefeld; Annette T Hastie; Eugene R Bleecker; Gregory A Hawkins Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-05-22 Impact factor: 5.464
Authors: R Duncan Hite; Bonnie L Grier; B Moseley Waite; Ruud A Veldhuizen; Fred Possmayer; Li-Juan Yao; Michael C Seeds Journal: Am J Physiol Lung Cell Mol Physiol Date: 2011-10-28 Impact factor: 5.464
Authors: Yasser O Mosaad; Mohamed A Baraka; Ahmed E Abou Warda; Hayam Ateyya; Mohammed A Hussein; Sayed Gaber Journal: Drugs Ther Perspect Date: 2022-06-27
Authors: Christina W Agudelo; Britta K Kumley; Estela Area-Gomez; Yimeng Xu; Abdoulaye J Dabo; Patrick Geraghty; Michael Campos; Robert Foronjy; Itsaso Garcia-Arcos Journal: PLoS One Date: 2020-02-06 Impact factor: 3.240
Authors: J Zebialowicz Ahlström; F Massaro; P Mikolka; R Feinstein; G Perchiazzi; O Basabe-Burgos; T Curstedt; A Larsson; J Johansson; A Rising Journal: Respir Res Date: 2019-11-06